Clinical Trial ResultsOlema presented updated Phase II data where the combo led to an impressive 13.1 month mPFS in prior CDK4/6i patients.
Drug DevelopmentOlema Pharmaceuticals has promising development opportunities with their complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), palazestrant (OP-1250), in the advanced/metastatic ER+ breast cancer treatment landscape.
Market PotentialThe stock price of Olema Pharmaceuticals is currently not reflecting the potential benefits in ESR1 wild-type patients or the first-line treatment opportunity, suggesting significant upside if these benefits are realized.